IL211810A0 - Therapeutic regimen comprising peg- interferon, ribavirin and vx-950 for the treatment of hepatitis - Google Patents

Therapeutic regimen comprising peg- interferon, ribavirin and vx-950 for the treatment of hepatitis

Info

Publication number
IL211810A0
IL211810A0 IL211810A IL21181011A IL211810A0 IL 211810 A0 IL211810 A0 IL 211810A0 IL 211810 A IL211810 A IL 211810A IL 21181011 A IL21181011 A IL 21181011A IL 211810 A0 IL211810 A0 IL 211810A0
Authority
IL
Israel
Prior art keywords
ribavirin
interferon
hepatitis
peg
treatment
Prior art date
Application number
IL211810A
Other languages
English (en)
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of IL211810A0 publication Critical patent/IL211810A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07Tetrapeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL211810A 2008-09-24 2011-03-17 Therapeutic regimen comprising peg- interferon, ribavirin and vx-950 for the treatment of hepatitis IL211810A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9984908P 2008-09-24 2008-09-24
US10965508P 2008-10-30 2008-10-30
US24304109P 2009-09-16 2009-09-16
PCT/US2009/058218 WO2010036799A1 (en) 2008-09-24 2009-09-24 Therapeutic regimen comprising peg- interferon, ribavirin and vx-950 for the treatment of hepatitis "

Publications (1)

Publication Number Publication Date
IL211810A0 true IL211810A0 (en) 2011-06-30

Family

ID=41396114

Family Applications (1)

Application Number Title Priority Date Filing Date
IL211810A IL211810A0 (en) 2008-09-24 2011-03-17 Therapeutic regimen comprising peg- interferon, ribavirin and vx-950 for the treatment of hepatitis

Country Status (11)

Country Link
US (2) US20110236351A1 (enExample)
EP (1) EP2328656A1 (enExample)
JP (1) JP2012503669A (enExample)
KR (1) KR20110074870A (enExample)
CN (1) CN102316935A (enExample)
AU (1) AU2009296653A1 (enExample)
CA (1) CA2738477A1 (enExample)
EA (1) EA201170484A1 (enExample)
IL (1) IL211810A0 (enExample)
MX (1) MX2011003121A (enExample)
WO (1) WO2010036799A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
EA201170441A1 (ru) * 2008-10-15 2012-05-30 Интермьюн, Инк. Терапевтические противовирусные пептиды
EP2396028A2 (en) * 2009-02-12 2011-12-21 Vertex Pharmceuticals Incorporated Hcv combination therapies comprising pegylated interferon, ribavirin and telaprevir
US20110082182A1 (en) * 2009-10-01 2011-04-07 Intermune, Inc. Therapeutic antiviral peptides
PT107894A (pt) 2011-10-21 2014-10-31 Abbvie Inc Métodos para o tratamento de hcv compreendendo pelo menos dois agentes antivirais de actuação directa, ribavirina, mas não interferão.
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
GB2515942A (en) 2011-10-21 2015-01-07 Abbvie Inc Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200700030B (en) * 2004-06-08 2009-06-24 Vertex Pharma Pharmaceutical compositions
MY141025A (en) * 2004-10-29 2010-02-25 Vertex Pharma Dose forms
CA2650616A1 (en) * 2006-04-26 2007-11-08 Vertex Pharmaceuticals Incorporated Hepatitis c virus infection biomarkers
MX2009012598A (es) * 2007-05-21 2009-12-07 Vertex Pharma Formas de dosis que comprenden vx-950 y su regimen de dosificacion.

Also Published As

Publication number Publication date
CA2738477A1 (en) 2010-04-01
MX2011003121A (es) 2011-04-21
EP2328656A1 (en) 2011-06-08
EA201170484A1 (ru) 2012-03-30
WO2010036799A1 (en) 2010-04-01
JP2012503669A (ja) 2012-02-09
US20130101554A1 (en) 2013-04-25
AU2009296653A1 (en) 2010-04-01
KR20110074870A (ko) 2011-07-04
US8871812B2 (en) 2014-10-28
CN102316935A (zh) 2012-01-11
US20110236351A1 (en) 2011-09-29

Similar Documents

Publication Publication Date Title
IL211810A0 (en) Therapeutic regimen comprising peg- interferon, ribavirin and vx-950 for the treatment of hepatitis
AP2907A (en) Viral hepatitis treatment
EP2318031A4 (en) IMPROVED METHODS AND DEVICES FOR ANTIVIRAL THERAPY
GB0602178D0 (en) Therapeutic treatment
IL213070A0 (en) Methods for the treatment of infections and tumors
EP2343066A4 (en) THERAPEUTIC AGENT FOR HEPATITIS C
GB0700436D0 (en) Impulse therapy for enhanced blood circulation in the body
IL193747A0 (en) New therapeutic combinations for the treatment of depression
HUE037109T2 (hu) Endoxifén rák kezelésében történõ alkalmazásra
GB0807018D0 (en) Antibodies and treatment
EP2004154A4 (en) THERAPEUTIC BELT
IL218279A0 (en) Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
ZA201000225B (en) Treatment of depression
ZA200901452B (en) Treatment of vertigo with acetyl-L-leucine
GB0608655D0 (en) Therapeutic Treatment
GB0816650D0 (en) Therapeutic bone grwth and regeneration
BRPI0714318A2 (pt) Utilização de 2-benzoil-imidazopiridinas em terapêutica
IL213593A0 (en) Hepatitis c virus combination therapy
PL2330892T3 (pl) Sposoby leczenia z zastosowaniem leków wychwytujących amoniak
GB0610909D0 (en) Therapeutic treatment
EP1881828A4 (en) TREATMENT OF HEPATITIS C (HCV) USING SUB-THERAPEUTIC DOSES OF RIBAVIRIN
ZA200809012B (en) Intravenous antiviral treatments
KR101992585B9 (ko) 정맥내 항바이러스 치료
ZA200905300B (en) Medicament for the treatment of endometriosis
FI8286U1 (fi) Kunto- ja terapiaväline